Disclaimer YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE. Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE? YES NO SJM-CV WEB-0718-0009 CARDIOVASCULAR CARDIOVASCULAR LIFE-CHANGING MEDICAL DEVICE TECHNOLOGIES AND SOLUTIONS THAT TREAT CARDIOVASCULAR CONDITIONS. FIND INFORMATION ABOUT CARDIOVASCULAR PRODUCTS AND THERAPIES FOR HEALTHCARE PROFESSIONALS FOR HEALTHCARE CONSUMERS & CAREGIVERS CARDIAC AND VASCULAR SOLUTIONS Healthcare professionals can find the information they need about innovations in cardiovascular technology that improve lives and help care for patients. GET PRODUCT DETAILS FOR HEALTHCARE PROFESSIONALS Find information to help you treat your patients with proven cardiovascular technologies and procedures. PRODUCT INFORMATION REIMBURSEMENT AND CODING MANUALS AND TECHNICAL RESOURCES EDUCATION AND TRAINING FOR HEALTHCARE CONSUMERS & CAREGIVERS We partner with your care team on your heart health so you and your loved ones can get back to living your life to the fullest. MANAGE YOUR ID CARD LIVING WITH YOUR DEVICE NEW FROM ABBOTT ABBOTT EXPANDS PERIPHERAL VASCULAR OFFERINGS WITH ACQUISITION OF WALK VASCULAR, LLC Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots. LATE-BREAKING DATA SHOWS ABBOTT'S AMPLATZER™ AMULET™ OCCLUDER OFFERS SUPERIOR LEFT ATRIAL APPENDAGE CLOSURE COMPARED TO WATCHMAN‡ DEVICE FOR PEOPLE WITH ATRIAL FIBRILLATION AT RISK OF STROKE The results of the trial show Abbott's Amulet device was superior for the primary endpoint of LAA closure and noninferior for the primary endpoints of safety and effectiveness versus the comparator device. GUIDE-HF STUDY DATA SHOW ABBOTT'S CARDIOMEMS DEVICE CAN IMPROVE CARE FOR MORE PATIENTS WITH HEART FAILURE Abbott today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS™ HF System in people living with NYHA Class II, III and IV heart failure. MAT-2005166 v4.0 Information contained herein for distribution outside the U.S. only. CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner. © 2021 Abbott. All Rights Reserved. MAT-2001111 v3.0